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with TM also activates thrombin activatable fibrinolysis inhibitor (TAFI).
However, the effect of the high plasma TM on fibrinolysis in TM-AC is unknown. Plasma from TM-AC cases and high-TM model control samples spiked with recombinant soluble TM showed reduced tissue factor-induced thrombin generation. Lysis of plasma clots from TM-AC cases was significantly delayed compared to controls, but was completely restored when TM/thrombin-mediated TAFI activation was inhibited. Clots formed in blood from TM-AC cases had the same viscoelastic strength as controls but also showed a TAFI-dependent delay in fibrinolysis. Delayed fibrinolysis was reproduced in high-TM model plasma and blood samples. Partial restoration of thrombin generation with rFVIIa or aPCC did not alter the delayed fibrinolysis in high-TM model blood. Our finding of a previously unrecognised fibrinolytic phenotype indicates that bleeding in TM-AC has a complex pathogenesis and highlights the pivotal role of TM as a regulator of haemostasis.
INTRODUCTION
Thrombomodulin (TM) is a type-1 transmembrane glycoprotein encoded by THBD and expressed at high levels on vascular endothelial cells 1 . TM binds thrombin with high affinity and changes its substrate specificity to favour protein C (PC), which when activated to APC down-regulates further thrombin generation by inactivating factors Va and VIIIa 2,3 . Consistent with this downregulatory role, reduced endothelial TM expression has been associated with disseminated intravascular coagulation 4 and venous thrombosis 5 . TM has also been linked to the pathogenesis of a dominant bleeding disorder caused by a THBD variant predicting a p.Cys537Stop substitution in the TM transmembrane domain. This results in high plasma TM levels, consistent with shedding of TM extracellular domain from the endothelium 6, 7 . It has been proposed that abnormal bleeding in this disorder, hereafter termed TMassociated coagulopathy (TM-AC), results from enhanced TM-mediated APC generation and suppression of further thrombin generation 6, 7 .
In addition to mediating APC generation, TM in complex with thrombin is also a potent activator of thrombin-activatable fibrinolysis inhibitor (TAFI) 8 .
Activated TAFI (TAFIa) cleaves carboxyl-terminal lysine residues from the fibrin surface thereby reducing binding of plasminogen and tPA, and downregulating fibrinolysis 9 ,10 . Here we describe the impact of high plasma TM levels on TAFI-mediated clot lysis in an unreported pedigree with TM-AC and reveal a previously unrecognised fibrinolytic component of the TM-AC phenotype.
METHODS

Study cases and coagulation studies
The study cases were enrolled to the NIHR BioResource rare diseases (UK REC 13/EE/0325) after informed written consent, in accordance with the Declaration of Helsinki. Plasma TM concentration was measured by ELISA (Abcam, Cambridge, UK). Calibrated automated thrombography (CAT) was performed on platelet poor plasma with the PPP LOW reagent (1 pM tissue factor (TF) and a Fluoroscan fluorimeter (Thermo-Fisher, Basingstoke, UK) 11 .
Experiments were also performed in high-TM model blood or plasma using samples from healthy controls spiked with 250-2500 ng/ml recombinant Cterminal truncated TM (Peprotech, Hamburg, Germany). THBD was analysed by whole genome sequencing through the BRIDGE-BPD project 12 and the ThromboGenomics high-throughput platform 13 .
Plasma fibrinolysis
Clots were formed in re-calcified, diluted plasma with 0.1 U/ml thrombin (Sigma-Aldrich, Poole, UK) as previously reported 14 in the presence of 300 pM recombinant tissue plasminogen activator (tPA; Genentech, San Francisco, Ca) and 16 µM phospholipids (Rossix, Molndal, Sweden). Clots were formed in the absence or presence of 500 ng/ml TM, 25 µg/ml potato tuber carboxypeptidase inhibitor (PTCI; Sigma-Aldrich; a TAFIa inhibitor) or 65 µg/ml MA-T12D11 (a monoclonal antibody inhibitor of thrombin/TMmediated TAFI activation 15 ). Turbidity was monitored every minute at 405 nm. 
Whole blood fibrinolysis
RESULTS and DISCUSSION
The study cases were males aged 59 and 34 years (I.1 and II.2; Figure 1A) with a lifelong propensity for muscle and joint bleeding after minor trauma.
Treatment of bleeding with plasma or Factor IX infusions was ineffective.
However, single 90 µg/Kg infusions of rFVIIa (NovoNordisk) were usually sufficient to resolve bleeding. Analysis of plasma by CAT showed that compared to healthy controls, the cases had reduced endogenous thrombin potential (ETP; 316.3 ± 51.5 nM/min (n=10) vs 1584.9 ± 56.2 nM/min in controls (n=20); P<0.01) and reduced peak thrombin concentration (71.7 ± 12.5 nM (n=10) vs 273.7 ± 19.6 nM in controls (n=20); P<0.01; Figure 1B , C).
Cases and controls showed similar lag time and time to peak thrombin. The plasma TM concentration in the cases was 640.7 ± 21.2 ng/ml (n=4; reference interval 2.9-7.6 ng/ml). No other abnormalities were observed in coagulation factor or anticoagulant protein levels ( Supplementary Table S1 ).
Consistent with this phenotype, both cases had heterozygous c.1611C>A transversions in the major THBD transcript NM_000361.2 which segregated in the pedigree with abnormal bleeding. This predicted p.Cys537Stop in the TM transmembrane domain, an identical variant to the two previously reported TM-AC pedigrees (Figure 1A) 6, 7 . Addition of sTM to control plasma caused dose dependent reductions in ETP and peak thrombin, that with 500 ng/ml sTM were similar to the cases (Figure 1C, D 
Fibrinolysis phenotype
Lysis of TM-AC plasma clots by tPA was significantly slower than controls (time to 50% lysis 175.1 ± 3.4 min (n=6) vs 103.1 ± 3.9 min in controls (n=3); P<0.01), and was reproduced in high-TM model plasma (time to 50% lysis 164.1 ± 8.6 min (n=3); P<0.01; Figure 2A, D) . Addition of MA-T12D11, which specifically inhibits thrombin/TM-mediated TAFI activation 15 , completely abrogated delayed fibrinolysis in the TM-AC and high-TM model plasma samples (Figure 2B, D) . Similarly, inclusion of the TAFIa inhibitor PTCI (25 µg/ml) also reduced the delay in fibrinolysis in TM-AC plasma, although did not completely reduce the 50% lysis time in the high-TM model to control levels (Figure 2C, D) .
Clots formed in TM-AC and high-TM model blood samples showed the same maximum clot firmness as controls (Figure 2E and Supplementary table   S1 ), indicating no differences in initial clot viscoelastic strength. However compared to controls, the time to 90% lysis was significantly delayed in TM-AC blood (time to 90% lysis 56.5 ± 2.3 min (n=7) vs 29.5 ± 3.5 min in controls (n=3); P<0.01) and in high-TM model blood (50.4 ± 2.0 (n=3); P<0.01; Figure   2E , F), indicating delayed fibrinolysis. Addition of PTCI 1-10 µg/ml caused a dose-dependent reduction in the delay in fibrinolysis in TM-AC and high-TM model blood samples (Figure 2E, F) , reproducing the effects in plasma.
Addition of 25-100 ng/ml rFVIIa or 0.25-0.75 U/ml aPCC, which partially restored thrombin generation in TM-AC and high-TM model samples, did not alter the delayed fibrinolysis in high TM-model blood (Figure 2G) .
We confirm that TM-AC is associated with reduced thrombin generation and reveal that delayed fibrinolysis is a component of the TM-AC phenotype using two experimental models. We show further that both phenotypes are a consequence of high plasma TM levels and that the delay in fibrinolysis is TAFIa-mediated, in line with the established role of TM/thrombin in TAFI activation 9 ,10 . It is significant that in the presence of high TM levels, enhanced TAFI activation occurred despite reduced thrombin generation and that partial restoration of thrombin generation with rFVIIa or aPCC did not alter the delayed fibrinolysis. This suggests that in TM-AC, TM rather than thrombin is 9 the main determinant of TAFI activation. Our findings highlight the complex multifactorial role of TM in the regulation of haemostasis and have important implications for the treatment of bleeding in TM-AC. Analyses were performed using a CS-21000i coagulometer (Sysmex AG, Horgen, Switzerland) using Seimens reagents, a Fluoroscan Ascent fluorimeter (Thermo-Fischer, Basingstoke, UK) and a ROTEM rotational viscoelastometer (Haemonetics, Braintree, MA) according to the manufacturers instructions using venous blood samples collected into 0.106 mM trisodium citrate. Coagulation assays for FVIII:C, FXI:C and FXI: C were one-stage APTT based assays. VWF:Ag was measured using the VWFAg immunoturbidimetric reagent and VWF:Rco using the BC VWF RCof activity kit. Protein C activity was determined using the Chromogenic PC activity kit and free protein S antigen with the Innovance free protein S kit. Plasminogen activity was determined using the Berichrom Plasminogen kit. *indicates mean± SEM for the results of replicate measurements (n=4-10) for patient (n=4-10) and model samples or healthy controls (n=20).
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